KERACNYL PP+
Anti-blemish cream
KERACNYL PP+ is indicated for the treatment of post inflammatory lesions and marks related to acne. Thanks to innovative and unique active ingredients, it acts on all the factors that cause acne.
KERACNYL PP+ is the solution to inflammatory acne, used alone or in combination with medicated treatments.
-
For whom?From age 12Adults
-
Price
-
TextureHypoallergenic.Non-comedogenic.Formula without AHA (Alpha-Hydroxy-Acids).
Patient relations
-
Application tips
Once or twice a day on dry skin, after cleansing with KERACNYL foaming gel.
-
In combination with the following treatments
Topical treatment: PBO, retinoids, antibiotic + retinoid combination, adapalene + PBO combination.
Mechanism of action
Patented combination of Myrtacin® + Celastrol: synergistic anti-inflammatory effects demonstrated by specifically targeting the immuno-inflammatory pathway involved in the physiopathology of acne.
Ingredients
Active ingredients:
100% natural and patented active ingredient, resulting from 15 years of research. It acts on the biofilm of C. acnes by limiting its formation and promoting its destruction.
1st innovative active ingredient from Pierre Fabre biotechnology (technique d’extraction brevetée), CELASTROL®, is of 100% natural origin and produced through the cultivation of plant cells.
Water-soluble vitamin, called niacinamide, nicotinamide or vitamin B3 essential to our metabolism.
Also called glyceryl laurate, this active ingredient has a sebum reducing activity, thanks to its inhibiting action of the 5α reductase, involved in the metabolism of androgens.
Formula details:
Click on an ingredient type to highlight it in the list
Clinical results and publications
Efficacy results
Effectiveness on inflammatory lesions (3).
Reduction of persistent marks at 1 month (4).
From the 1st application, in combination with medicated topicals (2).
Hydration (5).
Tolerance results
Tolerance only:
Very good skin and eye tolerance (1).
Tolerance in combination with other treatments:
Good tolerance in combination with topical drug treatments (2).
Legal Notice
Clinical safety and efficacy study in 41 adolescent and adult subjects with mild to moderate acne, with at least one post-inflammatory erythema and/or post-inflammatory hyperpigmentation. 2 applications per day for 12 weeks.
(1) Tolerance rated by investigators.
(3) Inflammatory lesion count using the Lucky method.
(4) Percentage of subjects with investigator-rated improvement in post-inflammatory marks (PIE/PIH).
(2) Clinical study of tolerance in combination with topical acne treatments in 39 adult women. 2 applications per day for 4 weeks
(5) Hydration kinetics 24 hours after a single application in 19 adult subjects.
Illustrative photos with polarized light
D1
D57
Discover the range
Contact us
Would you like to meet a sales representative?
Our medical sales representatives come to your workplace to answer all your questions about our brands and products.
The product concerned may not be available in your country. Please contact your medical sales representative for further information.
Have you noticed any side effects?
The safety and well-being of your patients is our priority. If you notice an unlisted adverse reaction to one of our products, please contact us without delay. We look forward to hearing from you!
Our commitments
Made in France
Product manufactured in our factories in France.
Conscious Care
Pierre Fabre Laboratories brands, including Ducray Dermatological Laboratories, have joined forces and collectively created Conscious Care: a dermo-cosmetic of the future that acts conscientiously towards its entire ecosystem.
Supporting associations
Ducray Dermatological Laboratories support 14 patient associations around the world, with the objective of sharing information on pathologies to improve their management.
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.